Portage Announces New Consultants For Its PPL-003 Development Programs

PPL-003 uses a new proprietary cell permeable peptide platform technology derived from human genes to deliver its anti-inflammatory cargo into the eye. who possesses extensive experience and expertise in the field of recombinant drug manufacturing will act as Director of Biotherapeutics Manufacturing and will be focused on developing a GMP process for PPL-003.

http://ift.tt/1x7PfOb